PMID: 16521412Mar 9, 2006Paper

Ciclesonide in the treatment of patients with bronchial asthma

Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
Tomasz TargowskiPatrycja Grabowska

Abstract

Inhaled glucocorticosteroids are the first choice drugs in the treating of patients with chronic bronchial asthma. Despite the fact that they are considered safe, in some percentage of patients they may cause local and even systemic side effects. Most of those side effects result from low lung / body deposition index of many glucocorticosterois and action of active metabolites of the drugs already in the oral cavity and throat. Ciclesonide is a new steroid characterized by clinical efficacy comparable to that of fluticasone and a lower risk of side effects. Ciclesonide is a prodrug, which is converted into an active metabolite by lung esterases only in the peripheral airways. Due to the use of a novel aerosol propellant--hydrofluoroalkane, available ciclesonide preparations are characterized by a high lung deposition. It is also characterized by low absorption to the systemic circulation. The article presents an current knowledge on pharmacokinetics, clinical efficacy and safety of ciclesonide in patients with bronchial asthma.

Related Concepts

Related Feeds

Asthma

This feed focuses in Asthma in which your airways narrow and swell. This can make breathing difficult and trigger coughing, wheezing and shortness of breath.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.